SK Plasma Begins Full-Scale Contract Manufacturing of Blood Products in Indonesia

SK Plasma, which is constructing a plasma fractionation plant in Indonesia, is set to fully launch its Indonesian blood product contract manufacturing organization (CMO) business.

Plasma imported to Pyeongtaek Port for Indonesia's blood product self-sufficiency is being transported to SK Plasma Andong Plant. SK Chemicals

원본보기 아이콘

On the 10th, SK Plasma announced that Indonesian plasma, which will be used for plasma fractionation product production, has arrived at its Andong plant in South Korea.

This is the first time Indonesian plasma has been imported to South Korea to ensure a stable supply of blood products based on the local population's blood. Until the local fractionation plant is completed, the Indonesian health authorities will send plasma secured through their national blood sources to SK Plasma, which will produce two finished products, 'albumin' and 'immunoglobulin,' at the Andong plant and supply them to Indonesia.

In 2023, SK Plasma established a joint venture, SK Plasma Core, with the Indonesian sovereign wealth fund and is constructing a blood product manufacturing plant in the Karawang Industrial Complex in Jakarta, aiming to operate in the fourth quarter of 2026 with an annual plasma fractionation capacity of 600,000 liters. Initially, before the new plant is completed, SK Plasma agreed to supply blood products, which are essential national medicines, in the form of CMO.

During the CMO period, technology transfer training for local Indonesian personnel will also be conducted at the Andong plant. The company plans to provide specialized technical education in various fields such as quality control and production to local personnel, nurturing them into bio-experts capable of stably producing and managing pharmaceuticals after the plant's completion.

This introduction of Indonesian plasma is the second case following the Singapore CMO contract. SK Plasma was selected as the first Asian contract manufacturer in the national bidding for blood products in Singapore, previously monopolized by multinational pharmaceutical companies, and has been supplying blood products since 2023.

Seungjoo Kim, CEO of SK Plasma, stated, "Due to the nature of pharmaceuticals made from blood as raw material, it is recommended to produce medicines using the plasma of the local population. However, since blood product production requires advanced technology and infrastructure, the market potential for CMO is very high," adding, "Based on the technology and solutions SK Plasma possesses, including CMO and local technology transfer, we plan to gradually expand our global business through collaboration with countries that require production technology."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.